Surgery is currently the only available treatment for AAA patients, although it is not always applicable or risk free. An effective drug therapy is greatly needed. We and others have shown that treatment with the peroxisome proliferator-activated receptor γ agonists rosiglitazone and pioglitazone was able to regress aneurysm formation in the angiotensin II (AngII)-induced mouse model of AAA [6, 7] . Pioglitazone was also shown to reduce macrophage infiltration in the vascular wall, an early feature of the AngII-induced aneurysms [6] [7] [8] [9] . An effective nonsurgical therapy that could inhibit this process may have a significant impact on AAA growth and stabilisation.
Since a recent meta-analysis of randomised controlled trials using thiazolidinediones resulted in their effective withdrawal, due to increased cardiovascular risk [10] , we used pioglitazone to identify new drug targets for the therapeutic treatment of aneurysm. We performed expression profiling of phorbol ester-differentiated THP-1 monocytic leukaemia cells that were treated with AngII or with AngII and pioglitazone. The polycystic kidney disease 1 (PKD1) gene was among the genes that were significantly up-regulated genomewide after multiple testing in our expression profile. Mutations in the PKD1 gene are the main cause of autosomal dominant polycystic kidney disease (ADPKD), which is also linked to an increased incidence of aneurysms in human and mouse models [11] [12] [13] [14] . Exploring its regulation further, we found that it is an early growth response 1 (EGR1) target gene, with EGR1 being a functional suppressor of PKD1 . EGR1 is immediately up-regulated during monocytic differentiation and recognises G/C-rich reach sequences in promoters of active genes [15] . Additionally, we show that AngII up-regulates PKD1 expression, that pioglitazone can ameliorate this effect and that removal of Egr1 from the haematopoietic compartment of mice abolishes aneurysm formation in a CaCl 2 -induced AAA experimental murine model.
Materials and Methods

Cells and Treatment
THP-1 cells (ATCC,
LGC standards, Teddington, UK) were maintained in RPMI 1640 (Sigma-Aldrich, Dorset, UK) supplemented with 10% (v/v) foetal bovine serum (Gibco, Life Technologies, Paisley, UK) and 1% (v/v) penicillin/streptomycin (SigmaAldrich, Dorset, UK) at 37 ° C in a 5% CO 2 -humidified incubator. Suspension THP-1 cultures were passaged at a ratio of 1/10 twice weekly. For experiments, the THP-1 cells were counted, seeded at 1 × 10 6 cells/ml and differentiated to macrophages in the presence of 100 n M phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich) for 4 h. After this 4-hour period, when the cells became adherent to the plate, PMA was washed off, and the monolayer was placed in growth medium (GM) alone (control cells), in GM with AngII (1 mg/ml; Bachem, Bubendorf, Switzerland) and in GM with AngII (1 mg/ml) and pioglitazone (1 μ M ; Sigma-Aldrich). Thereafter, the monolayers were harvested at 12, 24 and 48 h.
Microarray
The THP-1 cells were differentiated to macrophages by addition of PMA (100 n M ) for 4 h. The control THP-1 cells remained in the PMA, and the treatment cells were supplemented with AngII (1 mg/ ml) or AngII (1 mg/ml) and pioglitazone (1 μ M ) for another 24 h. At this time point, all cells, the PMA controls and the treated macrophages, were harvested for total RNA isolation with TRIzol TM (Life Technologies, Paisley, UK) according to the manufacturer's instructions. Biotinylated, high-quality amplified antisense RNA was prepared using the Illumina ® TotalPrep RNA amplification kit (Life Technologies, Paisley, UK) following the manufacturer's recommendations. The antisense RNA samples were hybridised to HumanHT-12 expression arrays (Illumina, Saffron Walden, UK). Subsequent staining of the hybridised arrays was performed with streptavidin-Cy3 (GE Healthcare, Life Sciences, Little Chalfont, UK) according to the manufacturer's recommendation (Whole Genome Gene Expression Direct Hybridisation assay; Illumina), and the arrays were scanned with an Illumina BeadStation GX500 (Illumina). The samples consisted of 3 experimental repeats for the following treatments: PMA only THP-1 cells, PMA and AngII-treated cells, and PMA and AngII/pioglitazone-treated cells. The data obtained from the chip readouts were adjusted using quantile normalisation and were analysed with the GeneSpring GX software. Statistically significant (i.e. p < 0.05) differentially expressed genes were identified using one-way analysis of variance (ANOVA) with the Tukey HSD post hoc test and multiple testing with the Benjamini-Hochberg for false discovery rate correction. Raw array data are accessible through the ArrayExpress database (EMBL-EBI; E-MTAB-2320).
Chromatin Immunoprecipitation with Quantitative PCR
Chromatin immunoprecipitation (ChIP) was performed as previously described [16] . Briefly, 8 × 10 7 -1 × 10 8 treated THP-1 cells were cross-linked with a solution of 1% (v/v) formaldehyde for 10-20 min at room temperature. The cell pellets were then washed and resuspended in a series of lysis buffers. Sonication at maximum output power (26 W/cm 2 ) at 4 ° C, for a total processing time of 7 min (14 × 30 s sonication sessions with 1 min rest intervals in between), was applied to obtain DNA fragments of 0.2-1.0 kb. From the resulting sonicated whole cell extract, a portion (1/38.5) was kept as input, and the rest was incubated overnight with Dynal Protein G magnetic beads (Life Technologies) coated either with 10 μg of EGR1 antibody (44D5; Cell Signaling Technology, New England Biolabs, Hitchin, UK) or normal rabbit IgG control antibody (2,729; Cell Signaling Technology, New England Biolabs). The beads were washed 6 times with RIPA buffer (Cell Signalling Technology, Danvers, USA) and 1 final time with TE/50 m M NaCl. Bound antibody-chromatin complexes were eluted at 65 ° C with brief vortexing every 10 min for 1 h. The input chromatin and antibody-chromatin complexes were further incubated at 65 ° C for 6 h for the reversal of the cross-links. The sonicated input DNA and the immunoselected DNA were then treated with RNase A and proteinase K and extracted with phenol:chloroform:isoamyl alcohol (24: 24: 1; Sigma-Aldrich). Purified DNA was then blunted with T4 DNA polymerase (Promega, Chilworth, UK), ligated to linker sequences and subjected to 2 sequential protocols of linker-medi- 
EGR1 Binding Site Analysis
The sequence of the promoter (±1,500-2,000 kb from the transcriptional start site) of the human polycystin-1 gene, PKD1 (ENSG00000008710), was accessed through the Ensembl human genome browser (www.ensembl.org/Homo_sapiens/Info/Index). The sequence was copied to the online tool for the search of putative transcription factor binding sites, TFSEARCH (www.cbrc.jp/research/ db/TFSEARCH.html), and the executed search returned, among other transcription-factor putative binding sites, an EGR1 binding site with a score of 94.5% within the proximal promoter of PKD1 (-322 bp from the transcription start site (TSS)). Primer sets were designed around this locus in order to determine EGR1 binding to this region. A primer set binding to a nearby locus was also designed to account for a locus-specific negative control (online suppl. fig. 1 RNA Extraction, cDNA and Quantitative Real-Time PCR For cDNA synthesis, the RNA was isolated from the THP-1 cells treated as above, using the RNeasy Mini Kit (Qiagen, Manchester, UK) with on-column DNase I digestion according to the manufacturer's instructions. Then, up to 3 μg of input RNA were randomly primed and reverse transcribed to cDNA using the GoScript Reverse Transcription System (Promega) f o llowing the manufacturer's recommendations. The selection of the most stably expressed reference genes for the THP-1 cells under the experimental conditions used for this work was done with quantitative real-time PCR (qRT-PCR) using the geNorm Reference Gene selection kit (Primerdesign, Rownhams, UK). The 12 genes included in the kit are shown in figure 2 of the online supplementary information. The results were analysed with the qBase + software (Biogazelle, Zwinjnaarde, Belgium). The mitochondrial succinate dehydrogenase ( SDHA ) and phospholipase A2 ( YWHAZ ) genes were found to be the most stably expressed reference genes in the THP-1 cells (online suppl. fig. 2 and table 3) , and therefore, they were used for the normalisation of the gene expression. The EGR1 and PKD1 expressions were validated by probe-based qRT-PCR prepared in duplicates from 3 independent experimental repeats. In each qRT-PCR, 25 ng (in 5 μl) of each cDNA sample were amplified using 1 μl of each double-dye-based probe, 10 μl of GoTaq Probe qPCR Master mix (Promega) and 5 μl of nuclease-free water under universal thermal cycling conditions (online suppl. table 3) in a CFX384 Touch cycler (Bio-Rad). The gene expression data were normalised against the average expression of the above reference genes and analysed using the comparative cycle threshold method.
Immunofluorescence
The THP-1 cells were grown in chamber slides (Nunc Lab-Tek Permanox, Fisher Scientific, Loughborough, UK) and treated as described above. After 24 or 48 h of treatment, the cells were washed twice with phosphate-buffered saline (PBS; Sigma-Aldrich), fixed with 4% (v/v) paraformaldehyde (Polysciences Inc., Park Scientific Ltd., Moulton Park, UK)/PBS at room temperature for 10 min and washed again twice with PBS. The cells were permeabilised with 0.1% Triton X100 (Sigma-Aldrich) in PBS for 5 min and washed twice with PBS. Blocking was performed in 20% foetal calf serum/PBS for 30 min at room temperature. The cells were incubated with rabbit polyclonal antibody to polycystin-1 (H-260; Santa Cruz sc-25570, Insight Biotechnology, Wembley, UK) followed by swine anti-rabbit FITC IgG (F0205; Dako, Cambridge, UK). The slides were counterstained with DAPI, mounted with aqueous mounting medium (ab128982; Abcam, Cambridge, UK) and visualised with a Zeiss Axiovert inverted fluorescence microscope (Zeiss, Jena, Germany). The images were acquired with a Leica TCS camera (Leica, Solms, Germany) using Zeiss AxioVision software (Zeiss).
RNA Interference
The freshly grown THP-1 cells were counted, and 5 × 10 4 cells were seeded in each well of a 24-well plate in 500 μl of GM with the transduction adjuvant polybrene (8 μg/ml; Santa Cruz, Insight Biotechnology). EGR1 short hairpin RNA (shRNA) (sc-29303-V; Santa Cruz, Insight Biotech) lentiviral particles (5,000 IFU/μl) that carry constructs encoding 3-5 target-specific shRNAs and a puromycin antibiotic resistance cassette were used at a multiplicity of infection of 5: 1. After 24 h, the polybrene was removed, and the cells were placed in GM and allowed to grow overnight. Next, the cells were split at a 1/5 ratio and allowed to grow further for 48 h. The selection of transduced clones was done with 2 μg/ml puromycin dihydrochloride (Santa Cruz, Insight Biotechnology), as determined by a puromycin killing curve. Thereafter, the medium was replaced every 3-4 days until surviving, growing, stably transduced THP-1 clones were selected.
Bone Marrow Chimeric Mice Generation
Male donor (8-week-old) homozygous deficient mice (B6N;129-Egr1 tm1Jmi/J ) (Jackson Laboratory, Maine, USA) were killed, and their femurs and tibias were removed aseptically. The marrow cavities were flushed out with Ca 2+ /Mg 2+ -free Hank's basal salt solution (Gibco), using a 25-gauge needle attached to a 1-ml syringe. Singlecell suspensions were prepared by repeated pipetting, and the resulting cell preparation was passed through a nylon mesh to remove particulate matter. The cells were washed twice in Hank's balanced salt solution, counted using a haemocytometer and resuspended at 3 × 10 7 cells/ml in RPMI 1640 before transplantation. Eight-weekold female wild-type litter mate recipient mice received a lethal dose of whole-body X-irradiation (950 rads). The irradiated recipients received 1 × 10 7 cells in 0.3 ml RPMI 1640 (Gibco) within 6 h of the irradiation via a tail vein injection. The repopulation was confirmed using fluorescence in situ hybridisation (FISH) for the Y chromosome (see below). CaCl 2 -induced aneurysms were generated in these chimeric mice 16 weeks after the bone marrow transfer.
Fluorescence in situ Hybridisation
Blood smears from the chimeric mice were collected at sacrifice, and the Y chromosome of the donor marrows was detected using a Y chromosome painting kit (Cytocell, Cambridge, UK) according to the manufacturer's recommendations. The resulting staining was visualised using a Zeiss Axiovert inverted fluorescence microscope, and the images were acquired with a Leica TCS camera using the Zeiss AxioVision software.
CaCl 2 -Induced Aneurysm Formation
All animal experiments were conducted with local ethical approval and reported according to the ARRIVE guidelines (https:// www.nc3rs.org.uk/arrive-guidelines). The CaCl 2 -induced model experiments were conducted using a number of minor modifications to those previously reported [18] . Mice (B6N; 129-Egr1 tm1Jmi/J ), aged 24 weeks, were anaesthetised to the surgical plane as described in the ARRIVE guidelines, then prepared for sterile surgical procedure and laparotomised 2-5 mm to the left of a central line. Abdominal aneurysmal dilation was induced (n = 10/group) between the renal arteries and iliac bifurcation following the measurement of the aortic diameter (μm) using computer-assisted micrometry (n = 5/animal) by an operator independent of the treatment. Dilation was induced by the application of 2 consecutive Whatmann TM 3MM ( GE Healthcare) rectangles (cut to the size of the artery), saturated with sterile 0.25 M CaCl 2 (Sigma-Aldrich) for 7 min (a total application time of 14 min). Excess CaCl 2 was then removed by swabbing the area with cotton buds soaked in 0.9% sterile saline prior to the closure of the wound. The mice were given an anaesthetic reversal agent (as described, ARRIVE report, suppl. file), and fully recovered before returning to the maintenance cages for 6 weeks. The animals were observed twice a day for signs of condition and weighed on alternate days to monitor their food intake. At 6 weeks after the induction, the animals were sacrificed by a lethal overdose of anaesthesia and cardiac puncture.
Statistical Analysis
The results are expressed as means ± standard error of the mean or as means ± standard deviation, as indicated. One-way ANOVA was performed using the GraphPad Prism 5 software with statistical significance assessed at p < 0.05. Aneurysm incidence was compared using Student's t test.
Results
Microarray Profiling of PMA-Differentiated THP-1 Cells
The global gene expression changes in the macrophages were identified using a microarray-based expression profiling. The THP1 cells were differentiated with PMA for 4 h followed by AngII, AngII/pioglitazone or no treatment control for a further 24 h. Expression profiling confirmed changes after this period, also reported elsewhere, that were relevant to the treatments applied, e.g. AngII treatment significantly up-regulated the expression of genes, such as MMP1 [19] and MMP12 [4] . Pioglitazone modulated the expression of genes that are known targets of peroxisome proliferator-activated receptor γ, such as FABP4 [20] along with others ( fig. 1 and online suppl. table 4). This initial analysis indicated that cultured PMA-differentiated THP-1s, followed by treatment with AngII or AngII and pioglitazone can recapitulate changes previously described for inflammatory cells in an aneurysmal setting (see gene ontological and pathway analyses, online suppl. fig. 3 and table 5). PKD1 was found to be among the genes significantly modulated in a genomewide analysis (using a corrected p value cut-off of p < 0.05 after applying a Benjamini-Hochberg multiple testing correction) after treatment with AngII or AngII and pioglitazone. The involvement of PKD1 in the increased incidence of aneurysms led to the following investigations.
A Putative EGR1 Binding Site at the Promoter of PKD1 Is Occupied by EGR1 after PMA-Induced Macrophage Differentiation and during Treatment with AngII or AngII and Pioglitazone
The differentiation of THP-1 cells to macrophages is concomitant with an abrupt and immediate up-regulation of the EGR1 protein, which returns to just detectable levels 48 h following the differentiation (online suppl. TMEM119   CH25H   PDGFRA   SYT11   LST1   CYBASC3   ZMYM2   EFNB2  PHLDA1  CD14  CAPRIN2  NCF1  GPC 4  DUSP5  CAPRIN2  FABP4  PBX4  MAP3K6  RDH10  PCOXL  PHLDA3  VCAM1  PLIN2  SLA  LOC542956  KCNK13  KIAA1851  IL1RN  ANGPTL4  DUSP1  TRNP1  GPR18  SHANK3  SHANK3  MMP19  MMP19  SPOCD1  UBE2E3  ADH4  PLIN2  CCDC109B  LOC387934  FGR  ITGA3  FGR  CAMK2D  MIR1974  FHL1  TMEM91  MSR1  TMEM140  ZNF618  GAS7  ABCC3 fig. 1 ). To determine whether EGR1 occupies this promoter region, we performed ChIP-qPCR. Immunoprecipitation of the cross-linked cells after PMA-induced differentiation and AngII, AngII/pioglitazone or no treatment control was performed with an EGR1 antibody, and the analysis of the immunoprecipitated fragments was achieved with primers flanking the putative EGR1 binding site (online suppl. fig. 1 ). The percent recovery of the immunoprecipitates relevant to input (non-immunoprecipitated chromatin) is shown in figure 2 a. Undifferentiated THP-1 cells express marginally detectable levels of EGR1, and therefore, they were used as a negative control for EGR1 recovery from the PKD1 promoter (i.e. 0.033 ± 0.005% of input). The percent recovery after 24 h, for all 3 conditions after PMA differentiation, AngII, AngII/pioglitazone and no treatment, ranged from 0.148 ± 0.064 (AngII/pioglitazone) to 0.205 ± 0.012% of input (AngII), confirming that EGR1 occupies its consensus site at the PKD1 promoter. The comparison of the levels of recovery from EGR1 binds at the PKD1 proximal promoter. a The percentage of recovery relative to input chromatin was measured using qPCR with primers flanking the putative EGR1 binding site. The binding of EGR1 at the EGR1 consensus of the PKD1 promoter was confirmed by the recovery of immunoprecipitated fragments for all 3 conditions tested after PMA-induced differentiation, no treatment (GM + Nil), AngII (GM + AngII) and AngII/pioglitazone (GM + A + P). Undifferentiated THP-1 cells (GM only) express just detectable levels of EGR1, and therefore, this condition was used as a negative control of EGR1 recovery from the EGR1 binding locus and for comparison with the other conditions. b Non-specific background recovery was very low, as measured by ChIP using an IgG antibody. c Primers designed around a non-EGR1-specific locus within the proximal promoter of PKD1 also showed very low recovery, confirming the specificity of the EGR1 recovery. The data represent the means ± standard deviation from 3 independent experiments with p values as indicated. AngII, AngII/pioglitazone or no treatment with the recovery from undifferentiated THP-1 cells showed that recoveries from AngII and no treatment conditions were significant (p < 0.05), but not from AngII/pioglitazone (p = 0.058). A low background ChIP noise was confirmed with IgG immunoprecipitation under the same conditions ( fig. 2 b) . In addition, in order to determine whether EGR1 localisation was specific and not an artefact of the ChIP-qPCR procedure, EGR1 recovery was assessed with primers flanking a nearby locus of the PKD1 promoter (1,074 bp downstream from TSS, online suppl. fig. 1 ). The very low levels of recovery ( fig. 2 c) from both EGR1 and IgG immunoprecipitants confirmed the specificity of the ChIP-qPCR technique. In PMA-differentiated THP-1 cells, after AngII or no treatment, EGR1 occupancy at the promoter of PKD1 was higher, but lower after AngII/pioglitazone treatment.
Role of EGR1 in Aortic Aneurysm
EGR1 Plays a Role in PKD1 Expression
In order to explore whether EGR1 binds at the PKD1 promoter in other cell types, we interrogated publicly available EGR1 ChIP-seq data from the ENCODE project (NCBI GEO, GSE32465). One common EGR1 peak upstream of PKD1 was identified in 5 out of 6 lines for which data were available, including Ecc1 endometrial epithelial cells, Gm12878 EBV-transformed B lymphocytes, H1 human embryonic stem cells, Hct116 colorectal carcinoma and K562 erythrocytes ( fig. 3 a) . Common to the 5 Fig. 3 . Analyses of available ChIP-seq data reveal a conserved EGR1 binding peak within the PKD1 proximal promoter of multiple cell lines. a Duplicate EGR1 binding peak coordinates for PKD1 were extracted from NCBI GEO (accession number GSE32465; part of the ENCODE project). Overlapping peaks were merged and graphically aligned to genomic loci (hg19) using R code based on Gviz and ggplot2 packages. A common conserved EGR1 binding peak within the PKD1 proximal promoter was identified in the above cell lines. The widths in the bar graphs indicate the position and heights proportional to the average 'score' values provided by ENCODE data. b Sequence of the conserved EGR1 binding peak within the PKD1 proximal promoter. c Four out of the above 5 cell lines also harbour EGR1 binding peaks within the PKD2 promoter. 276 bp ( fig. 3 b) that is located 203 bp upstream of the PKD1 TSS and encompasses the EGR1 consensus element discussed earlier (online suppl. fig. 1 ). No EGR1 peak was identified in Mcf7 mammary epithelial cells. In addition, 4 out of these 6 cell lines (except the Mcf7 mammary epithelial and the H1 human embryonic stem cells) harbour EGR1 binding peaks within their PKD2 gene promoter ( fig. 3 c) . Taken together, EGR1 binds at the PKD1 proximal promoter of multiple cell types, supporting a regulatory role for EGR1 in PKD1 expression.
EGR1 Suppresses PKD1 Expression during Differentiation, AngII Up-Regulates the Expression of PKD1 and Pioglitazone Ameliorates This Effect
In order to determine the effect of EGR1 binding at the PKD1 promoter, we checked the expression of PKD1 in PMA-differentiated THP-1 cells after AngII, AngII/pioglitazone or no treatment control for 12, 24 and 48 h by qRT-PCR. Increased expression of EGR1 coincided with lower expression of PKD1 , and reduced expression of EGR1 with increased expression of PKD1 over time, suggesting that EGR1 may suppress PKD1 expression in differentiating THP-1 cells ( fig. 4 a, b) . Treatment with AngII significantly up-regulated the expression of PKD1 by 24 h (p < 0.0001) and 48 h (p < 0.01). Parallel treatment with pioglitazone ameliorated the effect of AngII, and the expression levels of PKD1 were comparable to those in the no-treatment differentiated THP-1 cells for both 24 and 48 h. At the protein level, the expression of the PKD1 product, polycystin-1, was assessed by immunocytochemistry under the same conditions. Polycystin-1 was present in all 3 conditions for both time points. A representative staining after 48 h of treatment is shown in figure 4 c. Polycystin-1 staining was highly comparable between the no-treatment controls and the AngII/pioglitazone-treated cells and less prominent than in AngII-treated cells. These data in combination with the lower EGR1 occupancy at the PKD1 promoter after pioglitazone treatment ( fig. 2 a) strongly suggest that regulation of PKD1 expression under these conditions may involve other factor(s) and/or binding element(s) present in the PKD1 promoter.
EGR1 shRNA Lentivirally Transduced THP-1 Cells Express Higher Levels of PKD1
In order to verify the function of EGR1 binding at the PKD1 promoter, the THP-1 cells were stably transduced with lentiviral EGR1 shRNA for silencing the EGR1 expression. The undifferentiated EGR1 shRNA lentivirally transduced THP-1 cells showed no obvious phenotypic change from the non-virally transduced THP-1 cells. However, the PMA-induced differentiation of virally transduced THP-1 cells required a PMA-incubation 3 times longer for the cells to become adherent (12 instead of 4 h). PKD1 expression in the EGR1 shRNA lentivirally transduced cells was significantly higher (p < 0.0001) than that found in control non-virally transduced cells ( fig. 5 a) , as shown by qRT-PCR. The EGR1 expression was significantly depleted in the EGR1 shRNA virally transduced THP-1 cells (p < 0.0001; fig. 5 b) . Elevated levels of EGR1 seem to be required early on (initial time points), as low levels of EGR1 by 48 h did not affect PKD1 expression (no treatment controls, 48 h; fig. 5 a) . However, a lack of EGR1 at the initial time points reversed the effects of AngII and AngII/pioglitazone treatments in the EGR1 shRNA lentivirally transduced THP-1 cells. In those THP-1 cells where EGR1 had been silenced, AngII failed to induce an up-regulated PKD1 expression as it did when EGR1 was present, and AngII/pioglitazone treatment induced a significantly higher PKD1 expression. These data further suggest that EGR1 may co-operate with additional factors for the fine-tuning of PKD1 expression.
Deficiency of Egr1 in the Haematopoietic Compartment Inhibits Aneurysm Formation in a CaCl 2 -Induced Murine Model
We used an AngII-independent model to explore the role of Egr1 in aneurysm aetiology. We constructed bone marrow chimeric mice in which the haematopoietic compartment was reconstituted using marrow from homozygous deficient Egr1 mice in wild-type litter mates following bone marrow ablation. Control chimeric mice, reconstituted with wild-type bone marrow, produced 50% aneurysms following the aortic application of 0.25 M CaCl 2 , whereas in mice with Egr1 -deficient bone marrow no aneurysms were observed (n = 10, p = 0.048; table 1 ).
Discussion
Our findings support the role of macrophages in aneurysm development and define EGR1 as a key gene in this process. In the present study, we are showing that (1) EGR1 localises at the PKD1 proximal promoter; (2) AngII induces expression of PKD1 in differentiating macrophages, while pioglitazone ameliorates this effect; (3) EGR1 is a functional suppressor of PKD1 expression, and (4) Egr1 is necessary for CaCl 2 -induced aneurysm formation. Monocyte differentiation is accompanied by changes in expression and requires the involvement of multiple transcription factors, e.g. EGR1 [15, 21] , an immediate early induced factor. EGR1 binds to DNA G/C-rich sequences through 3 zinc-finger motifs in its carboxy terminal and modulates gene transcription through co-operation with other activating or repressing factors [15, 22, 23] . Experimental evidence has linked EGR1 induction to chronic vascular inflammation, and it is highly expressed in the intraluminal thrombus of AAA patients [23] [24] [25] [26] . Conversely, experimentally induced atherosclerosis and inflammation is greatly diminished in EGR1 deficient mice [25] . The PKD1 gene encodes polycystin-1, a complex, membrane-spanning glycoprotein that contains a uniquely large extracellular N-terminal ectodomain with a G protein-coupled receptor proteolytic site that can be cleaved from its transmembrane segment [27] . Intracellularly, polycystin-1 either interacts with the cytoplasmic tail of the PKD2 gene product, polycystin-2, or undergoes proteolytic cleavage to release a fragment from its C terminus, which translocates to the nucleus playing a role in gene transcription [28] . Mutations in the PKD1 gene are the cause of cyst formation in kidney, liver, pancreas and spleen, and they are linked to a high incidence of abdominal and intracranial aneurysms as well as to other cardiac defects [11-13, 29, 30] , suggesting a multifunctional/ multifactorial potential for polycystin-1. PKD1 is expressed in embryonic and adult kidney epithelial cells, but also in non-epithelial cells and in a variety of tissues and cells, from the vasculature (e.g. smooth muscle, endothelial cells) to hematopoietic cell lines [12, [30] [31] [32] . Consistent with our findings from THP-1 cells, the differentiation of K562 and HL60 cells to macrophages has been reported to coincide with the down-regulation of the PKD1 expression [32] . Similarly to THP-1 cells, K562 and HL60 cells also show an increase in EGR1 levels in response to PMA [33] , suggesting an EGR1-mediated suppression of PKD1 upon their differentiation to a macrophage lineage. PKD1 is tightly regulated; during early embryogenesis, it is highly expressed in many tissues and organs, but during adulthood it is maintained at low levels [34] . In ADPKD mouse models, PKD1 mutations resulting in loss of heterozygocity, haploinsufficency or overexpression trigger renal and extrarenal phenotypes with a varying degree of penetrance, supporting a gene dosage-dependent mechanism [12, 13, 30, [35] [36] [37] . PKD1 -/-mice, apart from kidney cysts, present aortic dissections that closely resemble the dissections of the AngII AAA mouse model [37] . The vascular fragility and aneurysmal phenotypes of the ADPKD mouse models support the involvement of polycystin-1 in altered extracellular matrix production, integrity and maintenance [12, 37] . In humans, ADPKD is also associated with aneurysms, which appear at a much greater incidence than in the rest of the population. The few studies that have assessed the frequency of aneurysms in the aorta report a higher prevalence from 1 to 10% in ADPKD patients [11, [38] [39] [40] . However, down-regulation of PKD1 in dissected human aortas has also been found independently of ADPKD in a gene expression profile analysis of patients that suffered acute aortic dissection of the ascending aorta, without having any other genetic background (e.g. Marfan's or Ehlers-Danlos syndrome) [14] . Similarly, whole genome expression profiling data showed PKD2 , a gene closely related to PKD1, to be one of the top most down-regulated genes in human AAA [41] .
EGR1 is an immediately induced transcription factor that has been shown to be involved in a variety of cellular responses from differentiation, growth and survival to growth arrest and apoptosis [21, 22] . In THP-1 cells, EGR1 expression is rapidly increased at the level of transcription, so there is an abrupt rise in the EGR1 mRNA and protein levels upon PMA stimulation. EGR1 binds to its consensus as a monomer and can be a direct/indirect activator of transcription depending on other interacting transcription factors, or a direct suppressor of transcription by displacement of a more positive factor (e.g. stimulating protein 1) [21, 26] . Multiple lines of evidence have so far shown that EGR1 does not act as a simple on/off switch of transcription; its mechanism of action seems to depend on a concentration equilibrium of interacting factors and chromatin conformation changes that may change affinities among shared binding sites, allowing active displacement of one transcription factor by another [21, 23] .
Our analysis of the PKD1 proximal promoter revealed a putative EGR1 binding site, which we confirmed to be occupied and functional. A binding site for EGR factors (EGRFs) had been previously documented in the proximal promoter of PKD1 in a study looking for conserved regulatory elements in multiple species [42] . The EGRF binding site was found to be conserved in mammals (i.e. humans, mice and dogs), but not in fish (i.e. Fugu rubripes ), suggesting a functional role specific for EGRFs in mammal PKD1 regulation. Other conserved transcription factor binding sites that have been identified in the proximal PKD1 promoter include multiple stimulating protein 1 [42, 43] , E26 avian erythroblastosis virus transformation-specific sequence [40] and myeloid zinc finger 1 [42] , the latter also pointing to a role for PKD1 in hematopoietic lineages. Further, our comparative analyses of already publicly available EGR1 ChIP-seq data revealed a conserved EGR1 binding site within the PKD1 promoter and EGR1 peaks within the PKD2 promoter. Since the expression of polycystin-1 and polycystin-2 is highly coordinated and the 2 proteins interact [34] , elements common to the promoters of PKD1 and PKD2 are likely to be involved in a conserved regulatory mechanism. The fact that EGR1 shRNA resulted in an up-regulation of PKD1 expression in differentiating THP-1 monocytes confirms such a functional regulatory relationship for the first time and assigns it, largely, to the EGR1 member rather than to other EGRFs.
Inflammation plays a fundamental role in the initiation, growth and rupture of aneurysms [2, 4, 5, 41] . Extensive research over the past two decades has revealed mechanisms by which continued oxidative stress can lead to chronic inflammation. This chronic inflammation can, over time, compromise the homeostatic mechanisms able to redress these events. A drug treatment for aneurysm stabilisation has to be able to perturb oxidative stress-induced inflammation on the one hand and, since the disease is largely asymptomatic for most of its development, has to also be a drug of 'no harm'. EGR1 is an important regulating factor in many target genes induced during chronic inflammation, such as tissue factor, ICAM-1 and IL-1β [26] . Blocking either EGR1 or its downstream targets may present a new therapeutic opportunity for aneurysmal stabilisation. The use of antisense RNAs against EGR1 did show some benefit in lung transplantation [44] . In addition, IL1β, a proven target of EGR1, as shown in the recently registered clinical trial (NCT02007252) exploring the therapeutic potential of IL1β antibodies on aneurysm growth, may support this mechanism.
